Osteopore (ASX:OSX) secures Hainan FDA approval at Shanghai Ruijin Hospital, opening an accelerated pathway into China’s US$2.5 billion orthopaedic devices market.
Healthcare Stocks
Aroa Biosurgery (ASX:ARX) printed NZ$12.6m EBITDA in FY26 then guided FY27 lower as it reinvests NZ$9m into Myriad and Symphony.
Ryman Healthcare (ASX:RYM) delivered NZ$188m positive free cash flow in FY26, its first in a decade, with EBITDAF up 94% and a FY28 dividend pathway in view.
IMEXHS (ASX:IME) wins a Zacatecas public tender for 20 hospitals, adding A$384k ARR and a showcase site for its agentic radiology AI stack.
Pacific Edge’s (ASX:PEB) FY26 revenue halved, but a news of a draft Medicare LCD for Cxbladder was good news
Alcidion (ASX:ALC) has signed its A$35m UHSussex EPR contract with A$8.5m recognised in FY26 via an upfront licence fee.
Oceania Healthcare (ASX:OCA) delivered FY26 EBITDA up 20% and cut net debt by NZ$121m, but pulled the dividend until cash flow turns positive.
Avecho Biotechnology (ASX:AVE) has locked in 244 patients for its Phase III insomnia interim analysis, with the late June 2026 readout now a hard date.
Avecho Biotechnology (ASX:AVE) has locked in 244 patients for its Phase III insomnia interim analysis, with results due late June 2026.
Adherium (ASX:ADR) has flagged a 100-to-1 share consolidation, aiming to lift its trading profile around the FDA-cleared Hailie platform.
